[Absorption, distribution, excretion and metabolism of a basic ether compound (R97) with antispasmodic activity]

Area of Science:

• Pharmacokinetics and Drug Metabolism
• Toxicology and Safety Studies
• Radiopharmaceutical Research

Context:

• Understanding drug behavior in vivo is crucial for pharmaceutical development.
• The study focuses on the disposition of a novel compound, 14C-R97.
• Investigating the absorption, distribution, excretion, and metabolism (ADME) provides essential safety and efficacy data.

Purpose:

• To elucidate the pharmacokinetic profile of 14C-R97 in rats following intravenous and oral administration.
• To determine the tissue distribution and routes of excretion of 14C-R97.
• To assess potential accumulation and transfer across biological barriers like the placenta.

Summary:

• Intravenous administration of 14C-R97 resulted in rapid distribution to major organs (liver, kidney, heart, lung), with minimal presence in blood after 5 minutes. No radioactivity was detected in the brain or eyes.
• Oral administration showed limited absorption, with radioactivity primarily confined to the gastrointestinal tract and predominantly excreted in feces (94% within 24 hours).
• Excretion via urine was approximately 12% within 24 hours. No significant transfer of radioactivity was observed in the fetus or placenta.

Impact:

• Provides critical ADME data for 14C-R97, informing potential therapeutic applications and safety assessments.
• Highlights differences in bioavailability between intravenous and oral routes, crucial for formulation development.
• Demonstrates a lack of placental transfer, suggesting reduced risk for fetal exposure.